A study on the efficacy of Gazyva, or obinutuzumab, found that the drug was able to curb cancer progression or relapse in 80% of patients with follicular lymphoma three years after treatment compared with approximately 73% of patients taking rituximab, according to findings published in The New England Journal of Medicine. The researchers did note, however, that the Gazyva also produced a greater number of side effects than rituximab.
Study compares lymphoma remission rates between obinutuzumab, rituximab
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.